RAC 2.92% $1.94 race oncology ltd

Ann: Second independent study shows Bisantrene inhibits FTO, page-50

  1. 973 Posts.
    lightbulb Created with Sketch. 11026
    Quite high numbers coming from a review in 2015 evaluating incidence of cancer and cardiovascular disease cases from only dietary arsenic. Considering water and environmental contamination play a role, this figure would be higher.

    https://hotcopper.com.au/data/attachments/3093/3093712-4297bf41428f51c48260fbf8862c6c10.jpg
    https://www.sciencedirect.com/science/article/pii/S0013935119300210?via%3Dihub

    Key point is that Bisantrene was shown to be effective in a cancer mouse model that overexpresses FTO.

    @RaceOncology I am wondering what your thoughts are on the xenograft transplantation in these mouse models. From what I have read, there are limitations in extrapolating mouse model findings to humans because transplantation site does not reflect host microenvironment. However, since the xenograft transplant in this model is a skin tumor and has been injected subcutaneously into the mice, I am thinking that there may be some similarities between the microenvironment and hence can be confident in the findings observed. Wondering if you have any commentary on that.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.94
Change
0.055(2.92%)
Mkt cap ! $330.4M
Open High Low Value Volume
$1.89 $1.96 $1.85 $333.0K 174.5K

Buyers (Bids)

No. Vol. Price($)
1 3105 $1.94
 

Sellers (Offers)

Price($) Vol. No.
$1.95 7574 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.